ADC Therapeutics
NJ - New Providence
BiotechnologyFocus: Antibody-drug conjugates
ADC Therapeutics is a life sciences company focused on Antibody-drug conjugates.
OncologyHematology
Funding Stage
PRIVATE
Open Jobs
6
Pipeline & Clinical Trials
Loncastuximab Tesirine
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)Clinical Trials (1)
NCT04705454Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
N/ALong-term Registry of Patients Treated With Loncastuximab Tesirine
B-Cell LymphomasClinical Trials (1)
NCT05160064Long-term Registry of Patients Treated With Loncastuximab Tesirine
N/AADCT-502
Breast CancerClinical Trials (1)
NCT03125200Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
Phase 1ADCT-601
Advanced Solid TumorsClinical Trials (1)
NCT03700294Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
Phase 1Loncastuximab Tesirine
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT05660395A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Phase 1ADCT-301
Acute Myeloid LeukemiaClinical Trials (1)
NCT02588092Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
Phase 1Loncastuximab Tesirine and Acalabrutinib
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT05971251Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Phase 1Camidanlumab tesirine
Hodgkin LymphomaClinical Trials (1)
NCT02432235Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Phase 1ADCT-601
Advanced Solid TumorsClinical Trials (1)
NCT05389462A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
Phase 1ADCT-901
Advanced Solid TumorsClinical Trials (1)
NCT04972981A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Phase 1Loncastuximab Tesirine
B-Cell Non-Hodgkin LymphomaClinical Trials (1)
NCT04970901A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Phase 1ADCT-402
Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT02669264Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Phase 1Loncastuximab tesirine and rituximab
Central Nervous System LymphomaClinical Trials (1)
NCT06607549Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Phase 1Loncastuximab Tesirine and Durvalumab
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT03685344Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
Phase 1Loncastuximab tesirine
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT04974996A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
Phase 1ADCT-402
Non-Hodgkin LymphomaClinical Trials (1)
NCT02669017Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Phase 1Autologous Hematopoietic Stem Cell Transplantation
Recurrent Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT05228249Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
Phase 1Phase 1
Clinical Trials (1)
NCT03621982Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1imvotamab
Non-Hodgkin LymphomaClinical Trials (1)
NCT04082936A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2Loncastuximab Tesirine
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT03684694Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT03698552ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Phase 1/2ADCT-301
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT04639024ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Phase 2Cyclophosphamide
Double-Expressor LymphomaClinical Trials (1)
NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Phase 2Loncastuximab Tesirine
Relapsed Follicular LymphomaClinical Trials (1)
NCT04699461Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Phase 2Epcoritamab
Large B-cell LymphomaClinical Trials (1)
NCT06919939Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Phase 2Loncastuximab Tesirine
Waldenstrom MacroglobulinemiaClinical Trials (1)
NCT05190705Loncastuximab Tesirine in WM
Phase 2Loncastuximab tesirine
Diffuse Large B-Cell Lymphoma RefractoryClinical Trials (1)
NCT03589469Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2Loncastuximab tesirine 150 µg/Kg
Marginal Zone LymphomaClinical Trials (1)
NCT05296070Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Phase 2Loncastuximab Tesirine
Diffuse Large B-cell LymphomaClinical Trials (1)
NCT05144009A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2Loncastuximab Tesirine
Relapsed or Refractory Large B-cell LymphomaClinical Trials (1)
NCT06788964Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Phase 2Loncastuximab tesirine
Follicular LymphomaClinical Trials (1)
NCT04998669Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 2Camidanlumab Tesirine
Relapsed Hodgkin LymphomaClinical Trials (1)
NCT04052997Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 2Odronextamab
B-cell Non Hodgkin LymphomaLoncastuximab Tesirine
Relapsed Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT04384484Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 3Open Jobs (6)
Associate Director, Financial Planning & Analysis (FP&A)
Remote
Finance1w ago
Administrative Assistant (contractor to perm)
New Providence, NJ
General & Administrative1w ago
Hematology Therapeutic Specialist (Pittsburgh)
Remote
Commercial1w ago
Vice President, Global Drug Safety
Remote
Clinical & Medical Development1w ago
Associate Director, Regional Marketing (Mid-Atlantic Region)
Remote
Commercial1w ago
Senior Director, Intellectual Property, Contract & Licensing Counsel
Remote
Legal3w ago
Interview Prep Quick Facts
Founded: 2020
Portfolio: 33 clinical trials
Open Roles: 6 active jobs
Hiring Trend
Actively Hiring
6
Open Roles
+6
Added
-0
Filled/Removed
Based on last 4 crawl cycles